<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04756804</url>
  </required_header>
  <id_info>
    <org_study_id>ZXZP0113</org_study_id>
    <nct_id>NCT04756804</nct_id>
  </id_info>
  <brief_title>Perioperative Patient Skin Antiseptic Preparation Evaluation</brief_title>
  <official_title>A Randomized, Controlled Clinical Trial Evaluating A Novel Perioperative Patient Skin Antiseptic Preparation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zurex Pharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zurex Pharma, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate a new topical skin antiseptic perioperative preparation and the&#xD;
      standard of care to determine efficacy on the rates of surgical site infections of surgical&#xD;
      patients. Safety will also be assessed.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 21, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Surgical Site infection occurrence</measure>
    <time_frame>Within 30 days after surgery</time_frame>
    <description>The primary objective is to demonstrate efficacy in surgical use through the rate of surgical site infections.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Allergic reaction and skin irritation</measure>
    <time_frame>Within 30 days after surgery</time_frame>
    <description>The primary safety objective is to determine the rates of skin irritation or allergic reactions attributed to each drug product and all other adverse events.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subgroup analysis of rates of surgical site infections</measure>
    <time_frame>Within 30 days after surgery</time_frame>
    <description>Surgical site infection rates by different infection types classified as superficial incisional infection, deep incisional infection, or organ-space infection.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subgroup analysis of rates of surgical site infections</measure>
    <time_frame>Within 30 days after surgery</time_frame>
    <description>Surgical site infection rates by type of surgery including clean (class I wound) or clean-contaminated (class II wounds) surgeries</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Surgical Site Infection</condition>
  <arm_group>
    <arm_group_label>70% Isopropyl Alcohol novel preoperative skin antiseptic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>70% v/v Isopropyl Alcohol novel preoperative skin antisepsis preparation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2% Chlorhexidine Gluconate/70% Isopropyl Alcohol preoperative skin antiseptic</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2% Chlorhexidine Gluconate/70% Isopropyl Alcohol preoperative skin antisepsis preparation</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>70% v/v Isopropyl Alcohol Surgical Solution</intervention_name>
    <description>Patient preoperative skin preparation</description>
    <arm_group_label>70% Isopropyl Alcohol novel preoperative skin antiseptic</arm_group_label>
    <other_name>ZuraGard</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2%w/v Chlorhexidine Gluconate / 70% v/v Isopropyl Alcohol</intervention_name>
    <description>Patient preoperative skin preparation</description>
    <arm_group_label>2% Chlorhexidine Gluconate/70% Isopropyl Alcohol preoperative skin antiseptic</arm_group_label>
    <other_name>ChloraPrep</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Be male or female and at least 18 years of age.&#xD;
&#xD;
          2. Be able to verbalize an understanding of the consent form, able to provide written&#xD;
             informed consent, verbalize willingness to complete study procedures, able to&#xD;
             understand written and oral instructions in English.&#xD;
&#xD;
          3. Be planning to undergo clean (class I wound) or clean-contaminated (class II wounds)&#xD;
             surgery.&#xD;
&#xD;
          4. Expect to be available for up to 30-days after the surgery.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Active infection or fever including evidence of infection at or adjacent to the&#xD;
             operative site.&#xD;
&#xD;
          2. Immunosuppressed.&#xD;
&#xD;
          3. Kidney/liver failure.&#xD;
&#xD;
          4. Immunosuppressive therapy (chemotherapy, steroids) within the previous 1 week.&#xD;
&#xD;
          5. Any history of allergy to chlorhexidine or isopropyl alcohol or any other component in&#xD;
             ZuraGard including citric acid, sodium citrate, methylparaben, or propylparaben, and&#xD;
             FD&amp;C Yellow #6.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph P Hart, MD, FACS, DFSVS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical College of Wisconsin</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Elizabeth Weseman, RN,BSN</last_name>
    <phone>414.955.1800</phone>
    <email>eweseman@mcw.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>MCW/FH</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>February 11, 2021</study_first_submitted>
  <study_first_submitted_qc>February 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 16, 2021</study_first_posted>
  <last_update_submitted>October 11, 2021</last_update_submitted>
  <last_update_submitted_qc>October 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Surgical Wound Infection</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethanol</mesh_term>
    <mesh_term>Chlorhexidine</mesh_term>
    <mesh_term>Chlorhexidine gluconate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

